Start here if you're new
what it is
BioVie tries to make drugs for brain disease and advanced liver disease.
how it gets paid
Last year Biovie made n/a in revenue. Bezisterim - Alzheimer’s disease was the main engine at $0M, or 25% of sales.
what just happened
BioVie posted -$1.70 EPS last quarter, and revenue was still not reported.
At a glance
C++ balance sheet — some cracks in the foundation
5/100 earnings predictability — expect surprises
-$12.12 fy2025 eps est
1.2 beta
~$11M market cap
xvary composite: 25/100 — weak
What they do
BioVie tries to make drugs for brain disease and advanced liver disease.
You do not own a wide moat here. You own 13 employees, two named programs, and one FDA Fast Track label on BIV201. Fast Track means the agency gives extra review help, not that approval is close. The contrast is plain: BIV201 has a path, while bezisterim is still investigational, which means still being tested.
How they make money
n/a
annual revenue
Bezisterim - Alzheimer’s disease
$0M
Bezisterim - Parkinson’s disease
$0M
Bezisterim - Long-Covid
$0M
BIV201 - cirrhosis and ascites
$0M
The products that matter
Parkinson's disease candidate
bezisterim
mid-2026 data catalyst
this is the near-term story. management points to the SUNRISE-PD study, with full data expected in mid-2026. If the efficacy signal is weak, the equity case breaks with it.
main catalyst
Alzheimer's disease candidate
NE3107
early, still unresolved
the program targets neuroinflammation, but the page is thin because the proof is thin. You are still waiting for efficacy to move from theory to investable evidence.
higher uncertainty
company-level funding need
capital access
$0.00 revenue base
for a pre-revenue biotech this small, financing is not background noise. It decides how long the pipeline gets to stay alive before the next raise.
survival variable
Key numbers
$11M
market cap
That is the whole company price. One good data read can move the tape hard from here.
13
employees
You are looking at a 13-person shop. That is a lab, not a factory.
1.2
beta
Beta (stock swing versus the market) at 1.2 means the shares move more than the index. That is extra noise on top of clinical risk.
$0M
ttm revenue
No sales means dilution is the bill. The market is funding the experiments.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (2% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for BIVI right now.
source: institutional data · return history unavailable
What just happened
missed estimates
BioVie posted -$1.70 EPS last quarter, and revenue was still not reported.
EDGAR shows the latest quarter at -$1.70 per share, or 121% worse than a year earlier. EPS (earnings per share, profit per share) was still negative, and the filing did not show a revenue number.
$0M
revenue
-$1.70
eps
n/a
n/a
the number that mattered
The -$1.70 EPS loss mattered because there was no revenue cushion in the filing.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is bezisterim failing to produce convincing SUNRISE-PD data. With $0.00 in revenue, there is no second engine keeping the equity case alive if that readout disappoints.
med
clinical failure
The near-term value of the company sits on bezisterim and the SUNRISE-PD trial. Full results are expected in mid-2026. If efficacy or safety disappoints, most of an ~$11M market cap could disappear fast.
this is the binary risk. The stock is small because the market knows it.
med
cash burn without revenue
BioVie reported $0.00 in product revenue for FY2025 and a $6.1M net loss in Q4 2025. That means every quarter without a financing solution or strong data keeps pressure on the balance sheet.
when there is no revenue base, dilution stops being a side issue and becomes part of the thesis.
med
timeline slippage
The bull case points to mid-2026 data. If that timing slips, the market loses the only clean catalyst on the calendar while losses keep running.
for a stock trading on anticipation, delays can hurt almost as much as bad data.
med
extreme volatility
The 52-week range is $1–$13 and price stability is 5 / 100. That is what a market looks like when conviction changes by the headline.
position sizing matters because the stock already trades like a verdict before the verdict arrives.
a failed or delayed Parkinson's readout would hit both sides of the story at once — confidence in the science and confidence in the financing path.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
mid-2026 SUNRISE-PD full data
This is the event that decides whether BIVI is a real neurology story or just another pre-revenue biotech with an expiring narrative.
conference
AD/PD 2026 presentation tone
Watch how much the conference abstract clarifies the Parkinson's signal. Investors in names this small read body language almost as closely as tables.
financial
quarterly loss trend
The latest quarter showed -$0.77 EPS and Q4 2025 net loss was $6.1M. If losses keep running with no new proof, the financing question gets louder.
risk
any sign the catalyst slips
When one date carries most of the equity story, delays are not administrative. They are thesis events.
Analyst rankings
earnings predictability
5 / 100
in human-speak, analysts do not trust this income statement to behave in a steady way
risk profile
5
risk rank 5 means this sits near the speculative end of the market, not the defensive end
source: institutional data
Institutional activity
institutional ownership data for BIVI is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive